INTRODUCTION {#sec0005}
============

Over 46 million individuals were estimated to suffer from dementia in 2015; their number is expected to soar to 74.7 million in 2030 and 131.5 million in 2050 \[[@ref001]\]. Alzheimer's disease (AD) accounts for 50--56% of all dementia cases \[[@ref002]\]. Since no effective pharmacological treatments are available \[[@ref003]\], non-pharmacological strategies are urgently needed.

Cognitive stimulation is a promising approach. Epidemiological studies have shown the beneficial effects of a cognitively active life, where stimulation is due to leisure activities \[[@ref004]\] rather than to the complexity of occupational tasks \[[@ref008]\]. Cognitive stimulation protocols have also been seen to improve patients' mood and mental function \[[@ref011]\]. However, the mechanisms underlying such benefits remain elusive.

Brain-derived neurotrophic factor (BDNF) may be involved in the effects of cognitive stimulation, since evidence from animal models of AD suggests that its modulation might contribute to the benefit achieved by environmental enrichment \[[@ref017]\]. Testing these findings in humans requires a simple, non-invasive, and inexpensive biological matrix. Blood is the ideal candidate. Circulating BDNF comes from a number of peripheral sources \[[@ref021]\], but may also derive from neurons and glial cells. Indeed, some experimental work suggests that the blood-brain barrier is permeable to the neurotrophin, although the agreement is not unanimous \[[@ref024]\]. A significant correlation has been documented in rats between BDNF concentrations in brain tissue and serum \[[@ref026]\]; more importantly, peripheral BDNF seems to reflect neural viability and integrity in healthy humans \[[@ref028]\] as well as widespread brain amyloidosis \[[@ref029]\], although Laske and colleagues \[[@ref030]\] failed to find a correlation between BDNF concentration in serum and cerebrospinal fluid in AD patients.

The above findings prompted us to test the effects of a comprehensive intervention (CI) on plasma BDNF (pBDNF) in AD patients, to assess the potential involvement of the protein in the effects exerted by the CI and explore the possibility of its biomarker use. The CI aimed primarily at cognitive enhancement through the improvement of some cognitive functions and of patients' motivation to remain active--- for instance via adoption of mnemonic strategies to compensate for deficits and/or participation in leisure activities and socialization--- and also provided advice on lifestyle and psychological support to patients and caregivers.

MATERIALS AND METHODS {#sec0010}
=====================

Participants were 85 healthy subjects (HE) and 80 patients with early AD. The study protocol complied with the principles of the Declaration of Helsinki (code SC/12/301) and was approved by the local ethics committee (INRCA Bioethics Advisory Committee, Ancona, Italy). The main characteristics of the two populations are summarized in [Supplementary Table 1](#S1){ref-type="supplementary-material"}. AD staging was based on the Clinical Dementia Rating Scale (CDR) \[[@ref031]\]: only patients with mild or moderate dementia (CDR 1 and 2) were included. The criteria for AD diagnosis and patient inclusion/exclusion in the study are described in the [Supplementary Material](#S1){ref-type="supplementary-material"}.

The CI consisted of 10 once weekly sessions of about 1 h. Its effect on pBDNF levels was tested immediately after the training sessions (FU1) and then at 6 (FU2) and 24 (FU3) months. Values were then compared to baseline.

The possible influence of acetylcholinesterase inhibitors, benzodiazepines, antidepressants, lipid-lowering medications, non-steroidal anti-inflamm-atory drugs, anticoagulants, antihypertensives, antidiabetics, and corticosteroids on pBDNF levels was taken into account. In particular, the use/non-use (dichotomous variable) of each drug class was established at baseline (HE group) and at baseline and FU1, FU2, and FU3 (AD patients). For each drug class, pBDNF levels were compared in subjects taking/not taking the medication. Smoking habits and alcohol consumption were assessed as described by Gagliardi et al. \[[@ref032]\].

Patients were randomly assigned to the experimental group (EG, *n* = 38) or the control group (CG, *n* = 42). Any further bias was excluded by comparing EG and CG patients for age, gender, marital status, years of schooling, and their scores on the Mini-Mental State Examination (MMSE), Geriatric Depression Scale (GDS), Activities of Daily Living (ADL), Instrumental ADL (IADL), and CDR. Significant differences were found for age (EG versus CG, 78.67±0.92 versus 76.11±0.72 years, *p* = 0.034) and ADL (4.95±0.20 versus 5.53±0.11, *p* = 0.015), leading to data adjustment for the two variables in all analyses. The CI was applied as described previously \[[@ref033]\]. Performance on the Alzheimer's Disease Assessment Scale-Cog test corrected for schooling (ADAS-Cog~score~) was the outcome measure.

Lithium heparin whole blood was collected at baseline and then at FU1, FU2, and FU3.

The pBDNF assay, CI, and statistical analyses are described in detail in the [Supplementary Material](#S1){ref-type="supplementary-material"}.

RESULTS {#sec0015}
=======

Baseline pBDNF {#sec0020}
--------------

Baseline pBDNF was significantly higher (*p* = 0.001) in AD than HE subjects (1.464 \[[@ref001]\] versus 0.984 \[0.83--1.16\] \[back-transformed mean and 95% confidence interval\]), but the difference ceased to be significant after adjustment for age and schooling. When AD patients were divided by disease stage, pBDNF was significantly higher in CDR 2 (*n* = 38) than HE subjects, also after the adjustment for age and schooling (*p* \< 0.001), whereas the difference between HE and CDR 1 (*n* = 42) subjects was not significant ([Fig. 1A](#jad-57-jad161168-g001){ref-type="fig"}).

pBDNF exhibited a significant, positive correlation with the MMSE score (*p* = 0.002) in HE subjects ([Fig. 1B](#jad-57-jad161168-g001){ref-type="fig"}) and with the ADAS-Cog~score~ (*p* \< 0.001) in AD patients ([Fig. 1C](#jad-57-jad161168-g001){ref-type="fig"}), whereas it was unrelated to age, schooling, GDS score, smoking habits, alcohol intake, and medications and, for AD patients, disease duration and age at disease onset.

Effect of the CI {#sec0025}
----------------

At FU1, the ADAS-Cog~score~ ([Fig. 2A](#jad-57-jad161168-g002){ref-type="fig"}) and pBDNF ([Fig. 2B](#jad-57-jad161168-g002){ref-type="fig"}) were significantly reduced in EG patients (both *p* \< 0.001), whereas in controls the difference was not significant. A significant, negative correlation was found in EG patients between the baseline ADAS-Cog~score~ and pBDNF changes from baseline and FU1 (*r* = --0.460, *p* = 0.005). No significant correlation was found in controls, indicating that the phenomenon is training-induced.

Follow-up {#sec0030}
---------

In CG patients, the ADAS-Cog~score~ showed similar values from baseline through FU3, whereas in EG patients values fell significantly from baseline to FU1 (*p* = 0.010), they reverted to baseline at FU2 (*p* = 0.016 vs FU1), and then increased further at FU3 (*p* = 0.001 and *p* \< 0.001 vs baseline and FU1, respectively) ([Fig. 2C](#jad-57-jad161168-g002){ref-type="fig"}). In CG patients, pBDNF was unchanged from baseline to FU3, whereas in EG patients FU2 values were significantly higher compared to both baseline (*p* \< 0.001) and FU1 (*p* \< 0.001), while a slight reduction was seen at FU3 versus FU2 (*p* \< 0.001 vs FU1) ([Fig. 2D](#jad-57-jad161168-g002){ref-type="fig"}).

Medications did not influence pBDNF at any follow-up point.

DISCUSSION {#sec0035}
==========

The major findings of this study are i) that baseline pBDNF was significantly higher in patients with moderate AD than in healthy individuals; ii) that baseline pBDNF was not significantly different in patients with mild AD compared with healthy individuals; and iii) that the CI exerted a positive short-term and a potentially negative long-term effect irrespective of disease stage.

Reports of blood BDNF in AD are conflicting \[[@ref034]\]. A possible explanation for the inconsistency is the lack of AD cohort overlap. The suggestion that changes in peripheral BDNF concentration may depend on AD stage \[[@ref046]\] has not been widely explored; however, even the studies that have addressed the issue have applied non-uniform criteria to define disease severity (i.e., use of MMSE rather than CDR score), preventing comparison of their findings. The possible difference between plasma and serum BDNF may provide another source of bias \[[@ref047]\]. Serum BDNF derives mainly from the thrombocyte storage pool, which is artificially released during experimental clotting \[[@ref048]\]. Platelets undergo several alterations during AD, including changes in membrane fluidity and cholesterol levels, abnormalities in cellular signal transduction, and atypical amyloid-β protein precursor metabolism \[[@ref050]\]. By influencing thrombocyte functioning these phenomena may exert different, even opposite effects on serum and plasma BDNF, especially considering thrombocyte hyperactivation \[[@ref051]\].

Although the inconsistent findings regarding circulating BDNF require further investigation, the present study provides information on the ability of pBDNF to be used to monitor AD progression, especially since it applied the CDR score for disease staging, excluded specific lifestyle influences, and investigated a broad medication panel including drugs that are commonly prescribed to the elderly but are not routinely evaluated, such as statins and antidiabetics \[[@ref052]\]. Although the mechanism underlying such stage dependence is unclear, it is conceivable that pBDNF increases as a consequence of advancing neuronal alteration. Support for the notion seems to come from the correlations, of different sign, detected between pBDNF level and cognitive status in our study participants, since higher pBDNF concentrations were associated to a better cognitive status in healthy controls and to a worse cognitive status in AD patients. The hypothesis has been advanced that increased circulating BDNF during physiological aging may be a neural reactive mechanism directed at preserving overall cognitive performance \[[@ref054]\], whereas in AD it could reflect an attempt to counteract the deficits induced by amyloid-β accumulation \[[@ref055]\] and/or to provide a trophic stimulus to compensate for neuronal loss \[[@ref057]\]. BDNF is known to play a key role in synaptic plasticity and neuronal survival \[[@ref058]\] and to be involved in several functions that undergo age- and dementia-related impairment such as learning, memory, and stress adaptation \[[@ref059]\]. In a recent study, gene delivery of BDNF in P301L transgenic mice has ameliorated several pathological features in this animal model of AD, suggesting a potential protective role for BDNF also in tauopathy \[[@ref062]\]. It is thus reasonable to hypothesize that structural/functional impairment worsens as AD progresses, triggering a greater demand for BDNF, thus establishing a vicious circle.

As regards the CI, an improved cognitive status (a significantly decreased ADAS-Cog~score~) and a significant pBDNF reduction were measured in AD patients immediately after the 10-week CI. Moreover, the significant negative correlation between baseline ADAS-Cog~score~ and pBDNF changes, detected in EG patients, suggests that the CI may exert a stronger effect on patients with more severe alterations, since higher baseline ADAS-Cog~score~ values were associated to a greater pBDNF reduction following the CI. Studies conducted in AD animal models show that environmental enrichment can reduce the amyloid-β burden, promote neurogenesis and cell survival, and improve synaptic transmission \[[@ref063]\]. The CI tested in the present study may have induced similar effects in our patients. This would at least partly explain the pBDNF modulation exerted by the CI, since a positive effect on neural dysfunction may conceivably involve a reduced BNDF demand.

However, the positive effect of the CI was transient. The ADAS-Cog~score~ reverted to baseline at FU2 and exhibited a further increase at FU3, while pBDNF showed a rebound effect at FU2. These findings suggest that CI interruption may involve a risk. Indeed, whereas control patients showed constant ADAS-Cog~score~ and pBDNF values throughout the study, the experimental group suffered a deterioration of the cognitive status and a further increase in pBDNF concentration compared to baseline. The frailty of AD patients' brain may at least partly explain these data, since a frail system exposed to a stressor usually fails to regain homeostasis after its end, and undergoes further deterioration \[[@ref067]\]. CI interruption, and the default of the trigger that induced functional (ADAS-Cog~score~) and molecular (pBDNF) changes at FU1 may have provided this type of stress event and have involved a worsening of the initial condition rather than a return to the previous equilibrium. This phenomenon, and the possible role of peripheral BDNF sources, deserve further investigation, since it cannot be excluded that the CI exerted secondary effects on circulating cells, which produce as well as store BDNF.

In conclusion, the present study showed that pBDNF, which is the "active" form of the molecule--- i.e., the fraction that is available for crossing the blood-brain barrier through a saturable transport system \[[@ref024]\]--- may serve as a peripheral biomarker to assess the effects of CIs in AD patients and indicated that more exhaustive information on the long-term consequences of CIs is needed before they can be introduced into clinical practice.
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======================

###### Supplementary Material

###### 

Click here for additional data file.
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![A) Baseline pBDNF was significantly higher in patients with moderate AD (CDR 2) than in healthy subjects (HE). B) In healthy subjects, a better cognitive status (higher MMSE score) was associated to a higher pBDNF. C) In AD patients, more impaired cognition (higher ADAS-Cog~score~) was associated to higher pBDNF. In A, columns and error bars represent back-transformed means and 95% confidence interval. In B and C, a constant was added to the log-transformed data to avoid showing negative values.](jad-57-jad161168-g001){#jad-57-jad161168-g001}

![A, B) Immediately after the intervention (FU1), ADAS-Cog~score~ and pBDNF values fell significantly in the experimental group (EG) but were not significantly changed in control patients (CG). C, D) In EG patients, the ADAS-Cog~score~ reverted to baseline at 6 months (FU2) and showed a further significant increase at 24 months (FU3) compared to baseline, while pBDNF increased significantly at FU2 compared to FU1 as well as baseline and fell at FU3 versus FU2. In CG patients, ADAS-Cog~score~ and pBDNF values were virtually unchanged throughout follow-up. In A and C, columns and error bars represent means and standard error of the mean; in B and C, columns and error bars represent back-transformed means and 95% confidence interval. Data were adjusted for age and ADL.](jad-57-jad161168-g002){#jad-57-jad161168-g002}
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